amylin — 23 things I got wrong before I got it right
amylin — 23 things I got wrong before I got it right. Making the case below, and I expect to lose some of it in the comments. Read the combination paper twice before saying anything here. The monotherapy and combination arms tell genuinely different stories. Sent a vial to Medutest because there was almost nothing on…
Independent purity data on this compound is sparse compared with the older molecules, simply because far fewer members have paid for testing. Sparse data means wide uncertainty, not a verdict.
Agreed — it is an amylin analogue and importing intuitions from the incretin boards produces confident nonsense.
Which receptor family are you attributing that effect to?
do not assume the dosing intuitions from the GLP-1 boards transfer
Small fix — amylin analogue, not a GLP-1 analogue. The whole mechanism argument changes on that word.
What does the tolerability table in that paper actually say?
Agreed — it is an amylin analogue and importing intuitions from the incretin boards produces confident nonsense.
Adding the standing caveat — nothing here is approved standalone and research material is not for human use.